Nifty
:
11329.95
Sensex
:
38408.84
29.50 (0.26%)
98.35 (0.26%)
Nifty
Sensex
:
:
11329.95
38408.84
29.50 (0.26%)
98.35 (0.26%)

Cipla Ltd.

Pharmaceuticals & Drugs - Global

Rating :
70/99

BSE: 500087 | NSE: CIPLA

NSE BSE
760.25
13-Aug-2020
  • Open
  • High
  • Low
  • Previous Close
  •  765.95
  •  782.90
  •  754.10
  •  762.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  13741283
  •  105525.69
  •  814.50
  •  355.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 61,311.67
  • 37.24
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 63,124.19
  • 0.53%
  • 3.77

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.68%
  • 4.33%
  • 16.38%
  • FII
  • DII
  • Others
  • 18.64%
  • 20.88%
  • 3.09%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.48
  • 4.73
  • 4.17

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.54
  • 4.61
  • 4.83

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.12
  • 3.04
  • 4.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.27
  • 33.50
  • 32.73

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.56
  • 3.36
  • 3.06

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.81
  • 16.38
  • 14.52

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
4,346.16
3,989.02
8.95%
4,376.19
4,403.98
-0.63%
4,371.00
4,007.54
9.07%
4,395.78
4,011.90
9.57%
Expenses
3,297.42
3,084.38
6.91%
3,742.67
3,442.93
8.71%
3,612.67
3,299.87
9.48%
3,486.28
3,309.68
5.34%
EBITDA
1,048.74
904.64
15.93%
633.52
961.05
-34.08%
758.33
707.67
7.16%
909.50
702.22
29.52%
EBIDTM
24.13%
22.68%
14.01%
21.82%
17.35%
17.66%
20.69%
17.50%
Other Income
65.45
78.37
-16.49%
93.18
95.36
-2.29%
72.13
78.53
-8.15%
100.52
132.57
-24.18%
Interest
46.00
52.12
-11.74%
53.00
44.78
18.36%
46.17
44.19
4.48%
46.07
44.37
3.83%
Depreciation
268.98
268.00
0.37%
345.80
510.28
-32.23%
277.89
293.13
-5.20%
282.96
281.90
0.38%
PBT
799.21
662.89
20.56%
327.90
501.35
-34.60%
506.40
448.88
12.81%
680.99
508.52
33.92%
Tax
227.78
192.24
18.49%
85.59
127.75
-33.00%
152.82
125.68
21.59%
200.55
142.39
40.85%
PAT
571.43
470.65
21.41%
242.31
373.60
-35.14%
353.58
323.20
9.40%
480.44
366.13
31.22%
PATM
13.15%
11.80%
7.11%
8.48%
8.09%
8.06%
10.93%
9.13%
EPS
7.09
5.84
21.40%
3.01
4.64
-35.13%
4.39
4.01
9.48%
5.96
4.55
30.99%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
17,489.13
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
Net Sales Growth
6.56%
4.70%
7.96%
5.29%
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
 
Cost Of Goods Sold
9,339.75
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
Gross Profit
8,149.38
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
GP Margin
46.60%
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
Total Expenditure
14,139.04
14,025.88
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
Power & Fuel Cost
-
327.43
335.11
298.82
251.73
245.92
228.28
218.63
233.12
235.35
198.55
% Of Sales
-
1.91%
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
Employee Cost
-
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
% Of Sales
-
17.67%
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
Manufacturing Exp.
-
1,372.03
1,284.94
1,220.67
1,192.77
1,596.79
737.11
644.42
541.58
583.18
627.94
% Of Sales
-
8.01%
7.85%
8.05%
8.29%
11.75%
6.50%
6.33%
6.54%
8.31%
9.93%
General & Admin Exp.
-
1,289.13
1,096.50
1,002.43
868.31
845.89
743.46
638.08
496.81
369.85
288.71
% Of Sales
-
7.52%
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
Selling & Distn. Exp.
-
1,252.04
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
% Of Sales
-
7.31%
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
Miscellaneous Exp.
-
766.82
855.40
968.98
645.54
83.99
497.67
441.10
355.12
194.07
386.67
% Of Sales
-
4.48%
5.23%
6.39%
4.48%
0.62%
4.39%
4.34%
4.29%
2.76%
1.77%
EBITDA
3,350.09
3,106.11
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
EBITDA Margin
19.16%
18.13%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
Other Income
331.28
369.38
476.57
357.65
228.69
208.21
165.55
265.37
222.14
139.52
91.68
Interest
191.24
197.36
168.43
114.23
159.38
206.63
168.29
145.74
33.91
38.34
25.10
Depreciation
1,175.63
1,099.95
1,097.15
949.83
1,322.93
754.22
504.71
372.64
330.48
312.22
273.33
PBT
2,314.50
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
Tax
666.74
631.20
569.53
250.11
179.76
331.59
400.03
463.38
544.31
306.51
195.22
Tax Rate
28.81%
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
PAT
1,647.76
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
PAT before Minority Interest
1,668.13
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
Minority Interest
20.37
47.00
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
PAT Margin
9.42%
9.30%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
PAT Growth
7.45%
3.18%
9.31%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
17.99%
 
EPS
20.46
19.79
19.18
17.55
12.58
17.03
14.97
17.39
19.26
14.17
12.01

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
Share Capital
161.25
161.14
161.02
160.90
160.68
160.59
160.58
160.58
160.58
160.58
Total Reserves
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
Non-Current Liabilities
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
Secured Loans
304.74
47.70
0.00
0.00
207.00
287.09
317.44
0.00
0.00
15.00
Unsecured Loans
2,064.54
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
Long Term Provisions
133.27
121.41
137.92
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
Current Liabilities
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
Trade Payables
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
691.77
720.88
Other Current Liabilities
706.65
541.86
647.04
908.95
1,006.14
654.55
408.67
250.89
489.93
235.28
Short Term Borrowings
447.15
486.16
435.87
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
Short Term Provisions
957.53
795.50
630.19
426.43
324.42
382.04
264.91
232.00
221.29
219.32
Total Liabilities
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
Net Block
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
Gross Block
15,009.61
13,665.08
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
Accumulated Depreciation
5,405.29
4,108.55
3,010.87
1,609.71
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
Non Current Assets
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
Capital Work in Progress
824.53
676.18
981.33
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
Non Current Investment
578.80
490.20
157.66
137.36
176.35
249.76
397.14
415.69
328.59
367.18
Long Term Loans & Adv.
670.59
455.57
514.96
543.67
426.18
1,860.78
1,552.40
978.96
865.38
841.20
Other Non Current Assets
84.10
166.82
255.71
210.06
176.54
168.39
151.74
154.88
38.95
30.98
Current Assets
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
Current Investments
1,016.52
2,125.79
1,102.21
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
Inventories
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
Sundry Debtors
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
Cash & Bank
1,003.91
618.81
965.61
638.27
871.40
564.26
175.76
143.01
90.46
95.97
Other Current Assets
1,416.84
415.99
480.20
418.17
1,223.17
858.67
630.63
468.31
622.17
726.59
Short Term Loans & Adv.
974.82
1,150.49
1,118.93
807.84
786.12
713.07
595.13
463.21
459.94
533.77
Net Current Assets
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
Total Assets
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
PBT
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
Adjustment
1,365.53
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
283.82
396.66
288.84
Changes in Working Capital
372.99
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
Cash after chg. in Working capital
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-848.25
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
Net Fixed Assets
-489.17
-173.15
-509.84
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
Net Investments
-1,439.15
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
Others
2,032.36
-255.79
6.92
-391.07
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
Cash from Financing Activity
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
Net Cash Inflow / Outflow
223.67
-326.26
223.27
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
Opening Cash & Equivalents
508.36
853.47
610.35
858.15
545.84
175.76
143.01
90.46
95.97
62.06
Closing Cash & Equivalent
742.38
508.36
853.46
610.35
858.15
564.26
175.76
143.01
90.46
95.97

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
194.85
185.62
175.92
155.15
142.23
133.38
124.79
112.21
95.03
82.91
ROA
6.56%
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
ROE
10.09%
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
ROCE
12.53%
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
Fixed Asset Turnover
1.88
1.80
1.25
1.36
1.40
1.26
1.47
1.69
1.61
1.79
Receivable days
54.10
55.36
68.17
61.60
57.62
57.94
58.66
70.11
77.94
87.29
Inventory Days
56.12
61.13
90.71
91.41
100.43
106.36
93.68
92.19
96.16
97.61
Payable days
57.55
59.02
57.37
46.96
48.81
52.17
44.93
48.58
50.51
56.11
Cash Conversion Cycle
52.66
57.47
101.50
106.05
109.24
112.14
107.41
113.72
123.59
128.78
Total Debt/Equity
0.18
0.29
0.29
0.33
0.46
0.16
0.12
0.11
0.00
0.09
Interest Cover
12.04
13.34
15.61
8.67
9.36
10.83
13.90
62.79
38.76
47.31

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Cipla reports 21% rise in Q1 consolidated net profit
    10th Aug 2020, 09:35 AM

    Total consolidated income of the company increased by 8.46% at Rs 4,411.61 crore for Q1FY21

    Read More
  • Cipla - Quarterly Results
    7th Aug 2020, 18:21 PM

    Read More
  • Cipla gets DCGI’s nod to launch Ciplenza in India to treat mild to moderate COVID-19
    25th Jul 2020, 08:48 AM

    The company will commercially launch Ciplenza in the first week of August priced at Rs 68 per tablet.

    Read More
  • Cipla all set to launch Favipiravir
    24th Jul 2020, 13:17 PM

    An off-patent anti-viral drug, Favipiravir, originally discovered by Fuji Pharma in Japan, has shown promise in clinical trials for treatment of COVID-19 patients, especially in mild and moderate cases

    Read More
  • Cipla, Amgen settle case involving generic cinacalcet hydrochloride tablets
    20th Jul 2020, 12:07 PM

    The resolution entitles the company and its affiliates to continue importing, marketing, and selling its generic cinacalcet hydrochloride tablets in the United States

    Read More
  • Cipla gets USFDA's nod for Icatibant Injectable Pre-Filled Syringe
    14th Jul 2020, 08:56 AM

    The company’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is APrated generic version of Shire’s Firazyr

    Read More
  • Cipla launches generic version of antiviral drug remdesivir
    9th Jul 2020, 09:15 AM

    Cipremi is priced at Rs 4,000 per 100 mg vial

    Read More
  • Cipla, Boehringer Ingelheim forge partnership to co-market three oral anti-diabetic drugs
    29th Jun 2020, 12:50 PM

    Empagliflozin is approved for glucose-control in patients with type-2 diabetes

    Read More
  • Cipla to price generic version of antiviral drug remdesivir at less than Rs 5,000 per vial
    24th Jun 2020, 14:11 PM

    The drug will be priced at less than Rs 5,000 per vial for injection 100 mg -- amongst the lowest pricing for remdesivir globally

    Read More
  • Cipla launches remdesivir under brand name CIPREMI
    22nd Jun 2020, 08:54 AM

    The USFDA issued a EUA to Gilead Sciences Inc. for emergency use of remdesivir for the treatment of hospitalized 2019 COVID-19 patients

    Read More
  • Roche Pharma India expands partnership with Cipla
    18th Jun 2020, 12:30 PM

    Roche Pharma India has signed a distribution agreement with Cipla

    Read More
  • Cipla signs agreements to acquire 21.85% stake in GoApptiv
    10th Jun 2020, 10:06 AM

    The company will strengthen its partnership with GoApptiv so as to enable widening reach of its key brands in the Tier 3+ towns

    Read More
  • Cipla reports 33% fall in Q4 consolidated net profit
    30th May 2020, 15:23 PM

    Total income of the company decreased by 0.67% at Rs 4469.37 crore for Q4FY20

    Read More
  • Cipla gets USFDA’s final approval for Dihydroergotamine Mesylate Nasal Spray
    21st May 2020, 09:06 AM

    The company is the first approved applicant for such CGT and, is therefore, eligible for 180 days of CGT exclusivity which will begin to run from the commercial marketing of Cipla’s product

    Read More
  • Cipla files ANDA for generic version of GSK’s Advair Diskus
    18th May 2020, 10:06 AM

    The company had recently announced the successful completion of its Phase-3 clinical end-point study for the product in the first attempt

    Read More
  • Cipla reports fall of 33% in Q4 consolidated net profit
    16th May 2020, 15:35 PM

    Total income of the company decreased by 0.67% at Rs 4469.37 crore for Q4FY20

    Read More
  • Cipla inks pact with with Gilead Sciences
    13th May 2020, 09:26 AM

    This agreement is part of company’s efforts to enhance global access to lifesaving treatments for patients affected by the pandemic

    Read More
  • Cipla gets EIR from USFDA for API manufacturing facility in Bangalore
    9th May 2020, 09:21 AM

    The agency had conducted inspection from January 20, 2020 to January 24, 2020

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.